These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9558174)
21. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346 [TBL] [Abstract][Full Text] [Related]
22. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. Gadsby K; Deighton C Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137 [TBL] [Abstract][Full Text] [Related]
23. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. Woo JH; Lee HJ; Sung IH; Kim TH J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Santra G; Sarkar RN; Phaujdar S; Banerjee S; Siddhanta S Singapore Med J; 2010 Nov; 51(11):883-7. PubMed ID: 21140116 [TBL] [Abstract][Full Text] [Related]
25. A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. Malaviya AN; Kapoor S; Garg S; Ahmad I; Raja RR J Assoc Physicians India; 2007 Mar; 55():193-7. PubMed ID: 17598330 [TBL] [Abstract][Full Text] [Related]
26. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S Platelets; 2010; 21(2):126-31. PubMed ID: 20050759 [TBL] [Abstract][Full Text] [Related]
27. The Swedish version of the Bath ankylosing spondylitis functional index. Reliability and validity. Cronstedt H; Waldner A; Stenström CH Scand J Rheumatol Suppl; 1999; 111():1-9. PubMed ID: 10503553 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Song IH; Rudwaleit M; Listing J; Sieper J Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168 [TBL] [Abstract][Full Text] [Related]
29. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237 [TBL] [Abstract][Full Text] [Related]
30. [Intravenous high dose glucocorticoids in patients with ankylosing spondylitis]. Rumiantseva OA; Bochkova AG; Liginova EIu; Kiseleva NM; Pushkova OV; Bunchuk NV Ter Arkh; 2006; 78(12):71-5. PubMed ID: 17294868 [TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557 [TBL] [Abstract][Full Text] [Related]
32. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444 [TBL] [Abstract][Full Text] [Related]
33. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Amital H; Applbaum YH; Aamar S; Daniel N; Rubinow A Rheumatology (Oxford); 2004 May; 43(5):658-61. PubMed ID: 14983108 [TBL] [Abstract][Full Text] [Related]
34. [Clinical study of etanercept for treating ankylosing spondylitis]. Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057 [TBL] [Abstract][Full Text] [Related]
35. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis]. Vinagre F; Santos MJ; Silva JC Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497 [TBL] [Abstract][Full Text] [Related]
36. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy. Tzelepis GE; Kalliakosta G; Tzioufas AG; Sfikakis PP; Mandros C; Boki KA; Roussos C; Moutsopoulos HM Ann Rheum Dis; 2009 Jun; 68(6):966-71. PubMed ID: 18633126 [TBL] [Abstract][Full Text] [Related]
37. Is disease severity in ankylosing spondylitis genetically determined? Hamersma J; Cardon LR; Bradbury L; Brophy S; van der Horst-Bruinsma I; Calin A; Brown MA Arthritis Rheum; 2001 Jun; 44(6):1396-400. PubMed ID: 11407700 [TBL] [Abstract][Full Text] [Related]
38. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. Gonzalez-Lopez L; Garcia-Gonzalez A; Vazquez-Del-Mercado M; Muñoz-Valle JF; Gamez-Nava JI J Rheumatol; 2004 Aug; 31(8):1568-74. PubMed ID: 15290737 [TBL] [Abstract][Full Text] [Related]
40. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Haibel H; Rudwaleit M; Listing J; Sieper J Ann Rheum Dis; 2005 Feb; 64(2):296-8. PubMed ID: 15208175 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]